ClinicalTrials.gg
Active, not recruitingNCT07284979KaiNETIC-3Updated Oct 6, 2026

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

A Phase 3 interventional study of Ribupatide and Semaglutide in Obesity, sponsored by Kailera. Active, not recruiting at 60 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Kailera · Phase 3, Interventional, and Treatment

Updated Oct 6, 2026Now Active, not recruitingEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing ribupatide in Obesity — 2 open to participants now, 9 under way, 6 of them phase 3. ribupatide · Obesity.

Enrollment
2nd of 16
1,270 · median 142
Started
2025
with 7 others
Phase 3
7 of 16
1 open now
Registered
12th of 16
by date
Lead sponsor
6 of 16
Kailera

Among the 16 studies testing ribupatide in Obesity, this one is the 2nd largest by enrollment, is one of 8 that started in 2025, is one of 7 in phase 3, and was the 12th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 16 studies testing ribupatide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ribupatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing ribupatide in Obesity, or all of them as a file.
02

Study summary

The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity
  • Ribupatide
  • KAI-9531
  • Glucagon-like peptide-1
  • GLP-1
  • Semaglutide
  • Glucose-dependent Insulinotropic Peptide
  • GIP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • ≥35 kilograms per square meter (kg/m\^2).
  • History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months.

Key Exclusion Criteria:

  • Current diagnosis or history of diabetes mellitus.
  • Started medications within 3 months prior to Screening that may cause significant weight change, including, but not limited to, tricyclic antidepressants, atypical antipsychotics, mood stabilizers, and phentermine.
  • Unstable weight defined as self-reported change in body weight exceeding 5% within the 3 months prior to Screening.
  • Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.
  • Uncontrolled hypertension or unstable cardiovascular disease.
  • History of chronic or acute pancreatitis.
  • Known gastric-emptying abnormality or chronic treatment with medications that directly affect gastrointestinal motility.
  • History of suicide attempt.
  • History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder.
  • Received treatment with semaglutide, tirzepatide, glucagon-like peptide-1 receptor (GLP-1R) agonist, GLP-1/glucose-dependent insulinotropic polypeptide (GIP), or glucagon receptor agonist within 3 months prior to Screening.

Note: Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,270 participants (actual)

Study arms

  • Experimental
    Ribupatide: Dose 1

    Participants will receive Dose 1 of ribupatide once weekly.

    Drug: Ribupatide

  • Experimental
    Ribupatide: Dose 2

    Participants will receive Dose 2 of ribupatide once weekly.

    Drug: Ribupatide

  • Active comparator
    Semaglutide

    Participants will receive semaglutide once weekly.

    Drug: Semaglutide

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to ribupatide once weekly.

    Drug: Placebo

Interventions

  • SC Injection

    Also known as: KAI-9531

  • SC Injection

    Also known as: Wegovy

  • DrugPlacebo

    SC Injection

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight at Week 76

    Time frame: Baseline, Week 76

Secondary outcomes

  1. Percentage of Participants with ≥10%, ≥15%, ≥20% and ≥25% Reduction in Body Weight

    Time frame: Baseline, Week 76

  2. Change From Baseline in Waist Circumference

    Time frame: Baseline, Week 76

  3. Change From Baseline in Absolute Body Weight

    Time frame: Baseline, Week 76

  4. Percentage of Participants with ≥5% Reduction in Body Weight

    Time frame: Baseline, Week 76

  5. Change From Baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 76

  6. Percent Change From Baseline in Fasting Triglycerides

    Time frame: Baseline, Week 76

  7. Percent Change From Baseline in Fasting High-density Lipoprotein (HDL)-cholesterol

    Time frame: Baseline, Week 76

  8. Percent Change From Baseline in Fasting Non-HDL-cholesterol

    Time frame: Baseline, Week 76

  9. Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score

    Time frame: Baseline, Week 76

  10. Percentage of Participants with ≥30% Reduction in Body Weight

    Time frame: Baseline, Week 76

  11. Change From Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 76

  12. Change From Baseline in Control of Eating Questionnaire (CoEQ) Craving Control Score

    Time frame: Baseline, Week 76

  13. Change From Baseline in CoEQ Positive Mood Score

    Time frame: Baseline, Week 76

  14. Change From Baseline in CoEQ Craving for Sweets Score

    Time frame: Baseline, Week 76

  15. Change From Baseline in CoEQ Craving for Savory Food Score

    Time frame: Baseline, Week 76

  16. Change From Baseline in CoEQ Hunger Score

    Time frame: Baseline, Week 76

  17. Change From Baseline in CoEQ Satiety Score

    Time frame: Baseline, Week 76

  18. Change From Baseline in CoEQ Combined Score

    Time frame: Baseline, Week 76

  19. Change From Baseline in Food Noise Questionnaire (FNQ) Score

    Time frame: Baseline, Week 76

  20. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 1 up to Week 80

  21. Number of Participants With Anti-drug Antibodies (ADAs)

    Time frame: Up to Week 80

  22. Number of Participants With Neutralizing Antibodies (Nabs)

    Time frame: Up to Week 80

  23. Plasma Concentrations of Ribupatide

    Time frame: Up to Week 76

07

Study locations

60 sites
  • Kailera Clinical Site
    Glendale, Arizona 85308, United States
  • Kailera Clinical Site
    Phoenix, Arizona 85012, United States
  • Kailera Clinical Site
    Little Rock, Arkansas 72205, United States
  • Kailera Clinical Site
    Northridge, California 91325, United States
  • Kailera Clinical Site
    Oceanside, California 92058, United States
  • Kailera Clinical Site
    Hamden, Connecticut 06517, United States
  • Kailera Clinical Site
    Stamford, Connecticut 06905, United States
  • Kailera Clinical Site
    Orange City, Florida 32763, United States
  • Kailera Clinical Site
    Albany, Georgia 31707, United States
  • Kailera Clinical Site
    Chicago, Illinois 60640, United States
  • Kailera Clinical Site
    Skokie, Illinois 60077, United States
  • Kailera Clinical Site
    Newton, Kansas 67114, United States
  • Kailera Clinical Site
    Shreveport, Louisiana 71105, United States
  • Kailera Clinical Site
    Farmington Hills, Michigan 48334, United States
  • Kailera Clinical Site
    Missoula, Montana 59804, United States
  • Kailera Clinical Site
    Las Vegas, Nevada 89148, United States
  • Kailera Clinical Site
    Albany, New York 12203, United States
  • Kailera Clinical Site
    Morehead City, North Carolina 28557, United States
  • Kailera Clinical Site
    Morrisville, North Carolina 27560, United States
  • Kailera Clinical Site
    Norman, Oklahoma 73069, United States
  • Kailera Clinical Site
    East Greenwich, Rhode Island 02818, United States
  • Kailera Clinical Site
    North Charleston, South Carolina 29405, United States
  • Kailera Clinical Site
    Spartanburg, South Carolina 29303, United States
  • Kailera Clinical Site
    Brownsville, Texas 78526, United States
  • Kailera Clinical Site #1
    San Antonio, Texas 78229, United States
  • Kailera Clinical Site #2
    San Antonio, Texas 78229, United States
  • Kailera Clinical Site
    Manassas, Virginia 20110, United States
  • Kailera Clinical Site
    Richmond, Virginia 23236, United States
  • Kailera Clinical Site
    Bruce, Australian Capital Territory 2617, Australia
  • Kailera Clinical Site
    Blacktown, New South Wales 2148, Australia
  • Kailera Clinical Site
    Kanwal, New South Wales 2259, Australia
  • Kailera Clinical Site
    Herston, Queensland 4006, Australia
  • Kailera Clinical Site
    Morayfield, Queensland 4506, Australia
  • Kailera Clinical Site
    South Brisbane, Queensland 4101, Australia
  • Kailera Clinical Site
    Camberwell, Victoria 3124, Australia
  • Kailera Clinical Site
    Pleven, Pleven Province 5800, Bulgaria
  • Kailera Clinical Site
    Plovdiv, Plovdiv Province 4000, Bulgaria
  • Kailera Clinical Site
    Sofia, Sofia 1606, Bulgaria
  • Kailera Clinical Site
    Sofia, Sofia 1618, Bulgaria
  • Kailera Clinical Site
    Varna, Varna Province 9000, Bulgaria
  • Kailera Clinical Site
    Montana, 3400, Bulgaria
  • Kailera Clinical Site
    Sofia, 1606, Bulgaria
  • Kailera Clinical Site
    Sofia, 1616, Bulgaria
  • Kailera Clinical Site
    Stara Zagora, 6000, Bulgaria
  • Kailera Clinical Site
    Krakow, Lesser Poland Voivodeship 30-033, Poland
  • Kailera Clinical Site
    Warsaw, Masovian Voivodeship 01-696, Poland
  • Kailera Clinical Site
    Gdynia, Pomeranian Voivodeship 81-384, Poland
  • Kailera Clinical Site
    Chorzów, Silesian Voivodeship 41-500, Poland
  • Kailera Clinical Site
    Bydgoszcz, 85-231, Poland
  • Kailera Clinical Site
    Gdynia, 81-338, Poland
  • Kailera Clinical Site
    Wroclaw, 51-162, Poland
  • Kailera Clinical Site
    Kielce, Świętokrzyskie Voivodeship 25-338, Poland
  • Kailera Clinical Site
    Exeter, Devon EX2 5DW, United Kingdom
  • Kailera Clinical Site
    Torquay, Devon TQ2 7AA, United Kingdom
  • Kailera Clinical Site
    Weymouth, Dorset DT4 0QE, United Kingdom
  • Kailera Clinical Site
    Glasgow, Glasgow City G51 4TF, United Kingdom
  • Kailera Clinical Site
    London, Greater London SE1 9RT, United Kingdom
  • Kailera Clinical Site
    London, Greater London SW1P 2PF, United Kingdom
  • Kailera Clinical Site
    Leicester, Leicestershire LE5 4PW, United Kingdom
  • Kailera Clinical Site
    Rotherham, South Yorkshire S65 1DA, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2028, 27 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 27 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Dec 16, 2025
StartActual
Dec 30, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Apr 2028
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 6, 2026
Sites
2 sites added, 1 site removed
Show 2 added (2 United States)
  • Kailera Clinical Site #1 · San Antonio, United States
  • Kailera Clinical Site #2 · San Antonio, United States
Show 1 removed
  • Kailera Clinical Site · San Antonio, United States
Oct 6, 2026
Enrollment
1200 (estimated)→1270 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Active, not recruiting
    2 sites added, 1 site removed
    Show 2 added (2 United States)
    • Kailera Clinical Site #1 · San Antonio, United States
    • Kailera Clinical Site #2 · San Antonio, United States
    Show 1 removed
    • Kailera Clinical Site · San Antonio, United States
    Enrollment 1200 (estimated)→1270 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07284979
Lead sponsor
Kailera
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Dec 30, 2025
Primary completion
Mar 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Oct 6, 2026

Study contacts

Medical Director
study director · Kailera Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion